Which one of the following statements regarding the new generation of antiplatelet drugs is not true?
A. Clopidogrel, prasugrel, and ticagrelor all inhibit the same receptor (P2Y12 ADP receptor)Clopidogrel and prasugrel are both pro-drugs, irreversible inhibitors, and once-daily regimes. The maintenance dose of prasugrel is halved for weight <60 kg or age >75 years. Clopidogrel is converted to its active metabolite by the cytochrome enzyme pathway; this accounts for the variability of action in some patients (hyporesponders) which can lead to stent thrombosis. Prasugrel is converted to its active form faster and more consistently. Ticagrelor is reversible and direct acting and therefore is again faster acting and more predictable than copidogrel. All inhibit the P2Y12 ADP platelet receptor.